Flow Cytometry Industry Overview

The global flow cytometry market size was estimated at USD 4.32 billion in 2023 and is projected to grow at a CAGR of 6.96% from 2024 to 2030.

The increasing incidence of cancer, immunodeficiency disorders, and infectious diseases is a key factor propelling market growth. Additionally, extensive research and development investments in biotechnology, life science, and biopharmaceutical research have contributed to a leveraged demand for flow cytometry instruments. For instance, in February 2023, Cytek Biosciences announced its plan to acquire the imaging and flow cytometry business from DiaSorin to expand its market share.

Gather more insights about the market drivers, restrains and growth of the Flow Cytometry Market

Flow cytometry is commonly used for the diagnosis of cancer and immunodeficiency diseases. The increasing prevalence of these diseases is one of the factors expected to drive the market over the forecast period. In addition, the adverse effects of chemotherapy & radiation therapy in cancer treatment have increased physicians' preference for autologous and allogeneic stem cell therapies, thereby positively impacting the growth of this market. According to data published by the American Cancer Society, in 2022, an estimated 1.9 million cancer cases were newly diagnosed in the U.S. Moreover, it also stated that around 0.60 million people died because of cancer.

Furthermore, key players are undertaking extensive strategic initiatives to new and advanced product developments. For instance, in January 2024, IDEX Health & Science introduced the new Semrock Nanopede Optical Filters tailored for flow cytometry applications. These filters cover the near UV and visible spectrum in 20 nm Full-Width, Half-Max (FWHM) increments, with the FWHM increasing to 30 nm in the near-infrared range. The Nanopede family includes 26 filters designed to meet specific application needs. This launch marks the initial step in expanding its product line to align with the dynamic market.

In addition, BD Biosciences has unveiled a significant technological advancement in Fluorescent Activated Cell Sorting (FACS), with the upcoming 50th anniversary of FACS in 2024. The BD FACSDiscover S8 Cell Sorter represents a milestone as the first spectral flow cytometer with sort-capable image analysis, offering the Canadian research community unprecedented insights and the ability to tackle previously unanswerable questions. Microfluidic miniature flow cytometry is expected to aid of adopting point-of-care diagnostics products, which is likely to be a key factor augmenting market growth. The introduction of multiplex reagents and probes for specific applications in drug discovery & diagnostics is expected to further create growth opportunities by catering to users in research laboratories and small peripheral laboratories. Moreover, digital signal processing has revolutionized the field of flow cytometry.

Browse through Grand View Research's Biotechnology Industry Research Reports.

  • The global biotechnology market was valued at USD 1.55 trillion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. 
  • The global biopreservation market size was valued at USD 2.18 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 28.30% from 2023 to 2030.

Flow Cytometry Market Segmentation

Grand View Research has segmented the global flow cytometry market report based on product, technology, application, end-use, and region:

Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Instruments
    1. Cell Analyzers
    2. Cell Sorters
  • Reagents & Consumables
  • Software
  • Accessories
  • Services

Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Cell-based
  • Bead-based

Flow Cytometry Application Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Research
    1. PharmaceuticalApoptosis
      1. Drug Discovery
      2. Stem Cell
      3. In Vitro Toxicity
    2. Cell Sorting
    3. Cell Cycle Analysis
    4. Immunology
    5. Cell Viability
    6. Others
  • Industrial
  • Clinical
    1. Cancer
    2. Organ Transplantation
    3. Immunodeficiency
    4. Hematology
    5. Autoimmune Disorders

Flow Cytometry End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Commercial Organizations
    1. Biotechnology Companies
    2. Pharmaceutical Companies
    3. CROs
  • Hospitals
  • Academic Institutes
  • Clinical Testing Labs

Flow Cytometry Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    1. U.S.
    2. Canada
  • Europe
    1. UK
    2. Germany
    3. France
    4. Italy 
    5. Spain
    6. Denmark
    7. Sweden
    8. Norway
  • Asia Pacific
    1. Japan
    2. China
    3. India
    4. Australia
    5. Thailand
    6. South Korea
    7. Singapore
  • Latin America
    1. Brazil
    2. Mexico
    3. Argentina
  • Middle East & Africa
    1. South Africa
    2. Saudi Arabia
    3. UAE
    4. Kuwait

Key Companies profiled:

  • Danaher
  • BD
  • Sysmex Corporation
  • Agilent Technologies, Inc.
  • Apogee Flow Systems Ltd.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Stratedigm, Inc.
  • Miltenyi Biotec
  • Cytek Biosciences
  • Sony Group Corporation (Sony Biotechnology Inc.)

Key Flow Cytometry Company Insights

The established players in the market such as Thermo Fisher Scientific, Inc., BD, and Danaher are strategically positioning themselves for sustained growth. Their activities include continuous research and development initiatives, strategic partnerships and acquisitions, and a focus on expanding their product portfolios. By leveraging their experience and market presence, these players aim to maintain leadership positions and adapt to evolving industry trends in the competitive landscape of flow cytometry.

Recent Developments

  • In March 2024, Beckman Coulter Life Sciences received 510(k) clearance from the FDA to distribute its DxFLEX Clinical Flow Cytometer in the U.S. This advancement makes high-complexity flow cytometry testing more accessible to laboratories without the need for additional expense.
  • In January 2024, Cytek Biosciences, Inc. agreed with the Centre for Genomic Regulation (CRG) and Pompeu Fabra University (UPF) to foster technological innovation and accelerate discoveries in the scientific community. The collaboration underscores the significant impact of Cytek's spectral flow cytometry technology, paving the way for expansion into new applications.

Order a free sample PDF of the Flow Cytometry Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter